Cardiac Endocrinology
Heart-Derived Hormones in Physiology and Disease

Juanjuan Zhao, PhD,a Liming Pei, PhDa,b

HIGHLIGHTS

- The heart uses an endocrine mechanism to communicate with the rest of the body.
- Heart-derived hormones, such as GDF-15, myostatin, and ANP/BNP, share common features, including synthesis, regulation, and function, and they coordinate the functions of the heart and target organs.
- Additional heart-secreted factors play important autocrine and/or paracrine roles in local cardiac remodeling.
- Future studies in the field of cardiac endocrinology will further advance the understanding of the intricate communications between the heart and the rest of the body.

SUMMARY

The heart plays a central role in the circulatory system and provides essential oxygen, nutrients, and growth factors to the whole organism. The heart can synthesize and secrete endocrine signals to communicate with distant target organs. Studies of long-known and recently discovered heart-derived hormones highlight a shared theme and reveal a unified mechanism of heart-derived hormones in coordinating cardiac function and target organ biology. This paper reviews the biochemistry, signaling, function, regulation, and clinical significance of representative heart-derived hormones, with a focus on the cardiovascular system. This review also discusses important and exciting questions that will advance the field of cardiac endocrinology. (J Am Coll Cardiol Basic Trans Science 2020;5:949–60) © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The vital function of the heart has been known for thousands of years. The heart beats continuously to pump blood that carries oxygen and nutrients to every cell of our body. An unhealthy heart, such as one with heart failure, has significantly reduced contractile function that reduces its ability to perform such a task. As a result, cells in our body receive less oxygen, nutrients, and other factors critical for their survival, growth, and normal function. In contrast, during exercise, the heart needs to elevate its rate and capacity to satisfy the increased whole body oxygen and energy demand. Therefore, it is of paramount importance that the heart communicates its functional status to the rest of the body to coordinate nutritional needs and functions.
Such heart-derived signals can take many forms and can be neuronal or endocrine in nature. Neuronal signals tend to be fast-acting, whereas endocrine signals can stimulate long-term changes. The heart can signal its functional status to the brain through sensory nerves; the brain then integrates and relays this information to the rest of the body through efferent nerves or endocrine signals (e.g., change in growth hormone level). Alternatively, the heart can secrete signals into the circulation that travel to distant sites of the body to directly affect their biology, thus functioning as heart-derived hormones. Such heart-derived hormones can be proteins, lipids, metabolites, or other forms of molecules. Most cell types routinely secrete many factors into the extracellular space, but most of them are often trapped there without going into the systemic circulation, or they go into circulation as mere biomarkers without specific biological functions through activating distinct receptors on specific target organs. Due to space limitations, this review mainly focuses on heart-derived endocrine hormones with systemic effects.

Compared with adipose tissue, liver, or muscle, the endocrine function of the heart is much less understood, with few heart-derived hormones identified and studied. The most well-established heart-derived hormones are atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), discovered almost 40 years ago (1–3), which play critical roles in vasodilation and natriuresis. Recent work from many laboratories, including ours, have identified or indicated new heart-derived hormones, such as growth differentiation factor (GDF)-15 and myostatin (4,5). A shared theme has emerged through these studies, which has helped define heart-derived hormones despite their biochemical diversity (Figure 1, Central Illustration): 1) they are synthesized and secreted from specific heart cells and enter the circulatory system; 2) their synthesis, maturation, secretion, and circulating levels are highly regulated in response to altered internal cardiac function or external cardiac demand; and 3) they act through specific receptors and signaling mechanisms in specific distant target organs and execute distinct biological functions to coordinate changes of cardiac function and demand (e.g., reduction of blood pressure by ANP/BNP, inhibition of body growth by GDF-15). Therefore, we refer to the study of these heart-derived hormones in physiology and disease as cardiac endocrinology.

We review known heart-derived hormones, focusing on GDF-15, myostatin, and ANP/BNP, and their biology in the cardiovascular system. We also briefly summarize additional heart-secreted factors with significant clinical relevance that largely function in an autocrine or paracrine manner to regulate local cardiac function. Last, we discuss important and exciting questions that remain to be answered in the field of cardiac endocrinology.

**GDF15**

GDF-15 is a divergent member of the transforming growth factor (TGF)-β family. GDF-15 was first discovered by several independent groups and was designated as macrophage inhibitory cytokine 1, placental bone morphogenetic factor, placental TGF-β, or prostate-derived factor (6–9). Gdf15 expression is low in most tissues under physiological conditions (8) but can be induced in the heart and other organs under pathological conditions, often with concomitant elevation of the circulating GDF-15 protein level (4,10–12). In the cardiovascular system, cardiac synthesis and secretion of GDF-15 are substantially increased in various cardiovascular diseases (e.g., heart failure) (13–15). In addition to serving as a useful serum biomarker of cardiovascular disease, heart-secreted GDF-15 was recently shown to slow pediatric body growth by inhibiting liver growth hormone signaling, thus functioning as a heart-derived hormone (4).

**BIOCHEMISTRY.** Human prepro-GDF-15 has a well-conserved N-terminal signal sequence of 29 amino acids and a C-terminal glycosylated pro-GDF-15 of 279 amino acids that tends to form a homodimer through an intermolecular disulfide bond (Figure 1A) (16). Three members of the proprotein convertase subtilisin/kexin (PCSK) family, PCSK3 (also known as furin), PCSK5, and PCSK6 have been shown to cleave pro-GDF-15 right after the conserved RXRXXR sequence both in vitro and in vivo, generating the mature GDF-15 dimer (17,18), which is the major circulating form of GDF-15 (19). The secretion of GDF-15 is little understood, and it is unclear whether GDF-15 exists in cellular granules before being secreted. Pro-GDF-15 has been observed in the extracellular matrix in studies of tumor cell lines, indicating that pro-GDF-15 can be secreted and that PCSK-mediated maturation can occur extracellularly (20,21). It remains to be discovered how circulating GDF-15 is cleared or degraded.

**RECEPTOR AND SIGNALING.** The receptor and signaling of GDF15 has long been elusive and debated, partly due to the high concentration of GDF-15 used in
most in vitro experiments (often hundred- to thousand-fold greater than physiological or pathological levels observed in vivo) and that some commercial sources of GDF-15 contain significant amount of contaminating TGF-β (22).

The recent identification of GDNF family receptor α-like (GFRAL) as a bona fide GDF-15 receptor represents a significant advance in our understanding of GDF-15 biology (23–26). These studies convincingly show that a GDF15 homodimer binds to a GFRAL homodimer, which then recruits and activates the receptor tyrosine kinase RET for downstream intracellular signaling (24,26) (Figure 1B). GFRAL contains a large extracellular domain (~330 amino acids) and a single transmembrane helix but has a short intracellular C-terminus without characterized kinase...
activity. GFRAL is reportedly expressed only in certain neurons located in the area postrema and nucleus of the solitary tract of the brainstem.

**REGULATION, FUNCTION, AND CLINICAL SIGNIFICANCE.** Numerous clinical studies have shown that the circulating GDF-15 level is increased in various heart diseases, including acute coronary syndromes and heart failure, and serves as a valuable diagnostic and prognostic biomarker for these diseases (13-15). The cardiac GDF-15 level is regulated at multiple levels, including synthesis and processing. The gene regulatory network that induces cardiac Gdf15 transcription was revealed using single-nucleus RNA-Seq in a genetic mouse model of heart disease (27), which indicated involvement of multiple factors (GATA4, unfolded protein response, and so on) in controlling GDF-15 synthesis. Heart disease also increases the transcription and protein level of PCSK5, thus promoting GDF-15 maturation at the same time (18).

Furthermore, recent studies revealed that GDF-15 executes important cardiovascular functions beyond serving as a biomarker. GDF-15 exhibits protective effects in mouse models of cardiac ischemia/reperfusion injury and hypertrophy induced by pressure overload (28,29), presumably acting via autocrine or paracrine mechanisms locally in the heart.

GDF-15 can also function as a heart-derived endocrine hormone that regulates pediatric body growth (4). Pediatric heart disease induces cardiac GDF-15 synthesis and secretion. Circulating GDF-15, in turn, acts on the liver to inhibit growth hormone signaling and body growth. Blocking cardiac production of GDF-15 via the AAV-delivered Gdf15 shRNA specifically expressed in cardiomyocytes normalizes circulating GDF-15 levels and restores liver growth hormone signaling, establishing GDF15 as a bona fide heart-derived hormone that regulates pediatric body growth. Plasma GDF-15 is further increased in children with concomitant heart disease and failure to thrive (FTT), providing a potential mechanism for the well-established clinical observation that children with heart diseases often develop FTT. Therefore, GDF-15 functions as a crucial endocrine signal for heart–body communication.

Outside of the cardiovascular system, GDF-15 produces strong appetite-suppressing and nausea-like effects that are completely dependent on GFRAL (23-26,30,31) and was proposed to mediate metformin’s effect on body weight and energy balance (32,33). Accordingly, genome-wide association studies and other genetic studies identified several loci next to the Gdf15 gene that are associated with hyperemesis gravidarum (rs16982345) (34), obesity (rs17724992) (35), and prostate cancer (rs1058587) (36), in addition to the risk of left ventricular hypertrophy (rs4808793) (37), highlighting the clinical significance related to GDF-15 biology. GDF-15-GFRAL is currently under extensive studies for 2 major therapeutic applications: activating GDF-15-GFRAL for treating metabolic disorders, including obesity, diabetes, and fatty liver disease (38,39); and inhibiting GDF-15-GFRAL for treating anorexia and cancer cachexia (31,40). Clinical trials for these implications are currently ongoing.

**MYOSTATIN**

Myostatin is another member of the TGF-β superfamily and was first discovered through screening in a mouse skeletal muscle library (5). A well-established negative regulator of muscle mass, myostatin is primarily expressed in skeletal muscle (5). Low levels of
myostatin can be found in normal hearts and are largely localized in Purkinje fibers (41).

Similar to GDF-15, myostatin is synthesized as a prepro-protein, which then undergoes glycosylation and homodimerization via an intermolecular disulfide bond (Figure 1A). Upon removal of the N-terminal signal sequence, the remaining pro-myostatin is further proteolytically processed by PCSK3 and the metalloproteinase bone morphogenetic protein 1 sequentially to become active (42,43). Although pro-myostatin can be cleaved by PCSK3 inside the cell, most pro-myostatin is believed to be secreted and processed extracellularly (44). After PCSK3 cleavage at the RXXR site, the myostatin dimer is associated with the remaining N-terminal region noncovalently as a latent complex until a second cleavage by bone morphogenetic protein 1 that generates the active form. It remains largely unknown how circulating myostatin is removed or degraded.

The receptors for myostatin are activin receptors (ActR), shared by other members of TGF-β family, including GDF-11 and activin-A. ActR includes 2 heteromeric single transmembrane serine/threonine kinases: type I (ActRI) and type II (ActRII). ActRII binds directly to myostatin, then recruits and phosphorylates ActRI (ALK4 or ALK5) at its cytosolic glycine-serine-rich (GS) domain which, in turn, phosphorylates and activates SMAD2/3 proteins (Figure 1B). Activated SMAD2/3 then inhibits skeletal muscle cell proliferation and protein synthesis through multiple mechanisms, including gene expression regulation and mTOR inhibition. Myostatin binds to both ActR type IIA (ActRIIA) and type IIB (ActRIIB) in vitro (45). However, transgenic mice that expressed a
dominant-negative form of ActRIIB mimicked the muscle phenotype of myostatin-deficient mice (42), which indicated ActRIIB is sufficient for myostatin inhibition on skeletal muscle growth in vivo.

Loss-of-function mutations of Mtsn (myostatin gene) led to widespread increase of skeletal muscle mass in both animals and humans (4,46), whereas overexpression of myostatin induced profound muscle loss in mice (47), which established myostatin as an essential regulator of muscle mass. A genome-wide association study identified several single nucleotide polymorphisms near Mtsn associated with racing performance in horses, and variations at ActRIIB gene Acvr2b were associated with handgrip strength in humans (48,49).

In the cardiovascular system, myostatin levels in both the heart and circulation are elevated in myocardial infarction or heart failure (50–53). The myostatin processing enzyme bone morphogenetic protein 1 activity was also increased in patient hearts with ischemic or dilated cardiomyopathy (52). Clinical studies showed that plasma myostatin level was positively correlated with heart disease biomarker N-terminal pro-BNP in patients with congestive heart failure and with infarct size in acute myocardial infarction, which indicated that myostatin is a potential biomarker for these heart diseases.

Cachexia and muscle wasting are often observed in severe heart disease (e.g., heart failure). Nkx2.5-cre–mediated, cardiac-specific deletion of Mtsn prevented skeletal muscle atrophy caused by heart failure (50), which suggested that cardiac-derived myostatin functions as an endocrine hormone acting on skeletal muscle. Therefore, myostatin-ActR signaling emerged as a promising target for muscle atrophy associated with heart failure. To this end, inhibition of myostatin-ActRIIB binding with an anti-myostatin blocking antibody JA-16 was shown to reverse skeletal muscle atrophy in mouse heart failure (50).

**ANP AND BNP**

Largely synthesized and secreted from the heart myocardiun, ANP and BNP have a well-established endocrine function that regulates whole body water and electrolyte balance (1–3). Similar to GDF-15 and myostatin, ANP and BNP are synthesized as prepro-peptides and cleaved by protease Corin or PCSK3, respectively, to release the mature active form (Figure 1A). Corin is, in turn, activated by PCSK6 (54).

The essential physiological function of ANP and BNP in regulating whole body hemodynamics is mediated through their specific receptors expressed in target tissues, including kidney, adrenal, brain, and vascular smooth muscle (55–57) (Figure 1B). Three types of natriuretic peptide receptors (NPRs) are known in mammals: NPR-A, NPR-B, and NPR-C. Upon natriuretic peptides binding, NPR-A or NPR-B catalyzes the production of the second messenger cyclic guanosine monophosphate, which further activates the broad downstream targets in different tissues (58–60). In contrast to NPR-A/B, NPR-C has a short intracellular domain that results in no guanylyl cyclase activity and no effect on intracellular cyclic guanosine monophosphate levels. NPR-C thus functions as a “clearance receptor” through internalization and balances the activities of circulating ANP and BNP (61–63). In addition, circulating ANP and BNP are cleared by the membrane-bound protease nephrilysin (64,65).

Although ANP and BNP are constitutively released under basal conditions primarily from the heart, their circulating levels are substantially induced in heart diseases via regulation at multiple levels: synthesis, processing, secretion, and degradation (66–68). ANP/BNP and their degradation enzyme neprilysin have emerged as clinically important biomarkers and/or therapeutic targets for cardiovascular disease (69,70). A combination drug of the neprilysin inhibitor sacubitril and the angiotensin II receptor inhibitor valsartan (Entresto, Novartis, Basel, Switzerland) was recently approved for patients with heart failure. In clinical trials, Entresto demonstrated further reduction of cardiovascular death, hospitalization, and all-cause mortality than widely used angiotensin-converting enzyme inhibitors alone (69,71,72).

**OTHER HEART-DERIVED HORMONES**

Additional heart-derived factors may potentially function in an endocrine manner. Mice with cardiomyocyte-specific loss of the transcriptional mediator complex protein MED13 gained more weight on a high-fat diet, although they exhibited no body weight change on a chow diet (73). Cardiomyocyte-specific overexpression of MED13 in mice conferred a lean phenotype by enhancing metabolism in white adipose tissue and the liver (74). Parabiosis experiments suggested that endocrine factors mediate such metabolic changes (74). Similarly, cardiomyocyte-specific overexpression and knock-out of G-protein–coupled receptor kinase 2 also altered adipose metabolism potentially through endocrine mechanisms (75). In both cases, the exact identities of possible heart-derived endocrine factors...
that mediate reported metabolic effects remain to be discovered.

HEART-DERIVED AUTOCRINE AND/OR PARACRINE FACTORS

Cardiac cells such as cardiomyocytes, fibroblasts, and endothelial cells can secrete a large number of factors in various forms from proteins, lipids, and small molecules to exosomes. In addition to GDF-15, myostatin and ANP/BNP, some of these factors have been reported to enter systemic circulation. However, it remains unknown whether the strictly heart-derived portion of these factors in circulation (e.g., in a heart-specific knock-out setting) have specific biological functions on distinct target organs. In contrast, many of the cardiac cell–secreted factors enter the local extracellular environment without going into systemic circulation. Many of them have been shown to function in local cardiac remodeling by acting in an autocrine or paracrine manner. Their functions are summarized in Table 1, and we focus our discussion on those with significant clinical relevance.

C-TYPE NATRIURETIC PEPTIDE. Unlike ANP and BNP, C-type natriuretic peptide (CNP) is widely expressed and not heart-specific (117,118). However, cardiac synthesis of CNP is substantially elevated in patients with chronic heart failure (79), and CNP regulates cardiac function through its receptor NPR-B in the heart (119–121). Cardiac-specific overexpression of CNP in rats had no effect on the infarct size upon ischemia/reperfusion injury but prevented the following hypertrophy (80). Systemic infusion of CNP significantly reduced hypertrophy and fibrosis after myocardial infarction in mice (81). Cardiomyocyte-specific deletion of CNP showed deteriorated heart function in a pressure-overload injury model (82).

| TABLE 1 Heart-Derived Hormones and Autocrine/Paracrine Factors | Pathophysiological Role | Clinical Relevance | Ref. # |
|---|---|---|---|
| **Endocrine hormones** | | | |
| ANP | Natriuresis and vasodilation | HF | (67,71) |
| BNP | Natriuresis and vasodilation | HF, biomarker | (70,71) |
| GDF-15 | Inhibiting body growth | Biomarker for ACS, HF | (13-15) |
| Myostatin (GDF-8) | Reducing skeletal muscle mass | HF, AMI, cardiac cachexia | (50,52,76,77) |
| **Autocrine/paracrine factors** | | | |
| Activin A | Protecting cardiomyocyte | MI | (78) |
| CNP | Vasodilation | HF, CH | (79–83) |
| CTRP9 | Cardioprotection | CH, MI, HF | (84–86) |
| ET-1 | Promoting cardiomyocyte survival | HF | (87) |
| FGF-2 | Inhibition of excessive autophagy and increase of ubiquitinated protein clearance | MI | (88–90) |
| FGF-9 | Preserving systolic function | MI | (91) |
| FGF-16 | Preventing cardiac hypertrophy and fibrosis | CH | (92) |
| FGF-21 | Regulating cardiac metabolism; antihypertrophic | AMI, CHD, HF, DCM | (93,94) |
| FGF-23 | Promoting fibrosis and diastolic dysfunction | CH, MI | (95,96) |
| FSTL1 | Cardioprotection | HF, ACS, CH | (97–101) |
| FSTL3 | Antagonizing Activin A cardioprotection | MI, CH | (78,102) |
| IL-33/sST2 | Antihypertrophic and antifibrosis | AMI, HF, CH | (103,104) |
| MANF | Cardioprotection | MI, CH | (105,106) |
| miRNA-1/208ab(3)/499/30a | Post-transcriptional regulation | AMI | (107–111) |
| PI16 | Inhibiting hypertrophy | HF, CH | (112) |
| sFRP2 | Antagonist of Wnt signaling | MI | (113,114) |
| sFRP3 | Antagonist of Wnt signaling | HF, MI, ACS | (115,116) |
| **AMI** | acute myocardial infarction; **ACS** | acute coronary syndrome; **ANP** | atrial natriuretic peptide; **BNP** | brain natriuretic peptide; **CH** | cardiac hypertrophy; **CHD** | coronary heart disease; **CNP** | C-type natriuretic peptide; **CTRP9** | C1q/tumor necrosis factor-related protein-9; **DCM** | diabetic cardiomyopathy; **ET** | endothelin; **FGF** | fibroblast growth factor; **FSTL1** | follistatin-like 1; **GDF** | growth differentiation factor; **HF** | heart failure; **IL** | interleukin; **MANF** | mesencephalic astrocyte–derived neurotrophic factor; **MI** | myocardial infarction; **miRNA** | microRNA; **PI16** | protease inhibitor 16; **sFRP** | secreted frizzled-related protein; **sST2** | soluble suppression of tumorigenesis-2. |
FOLLISTATIN. The follistatin family of proteins are a group of secreted glycoproteins that bind and neutralize TGF-β family factors. Cardiac synthesis of follistatin-like 1 (FSTL1) and 3 (FSTL3) are elevated in human heart failure and in rat models of hypertrophic cardiomyopathy induced by pressure overload (97). Serum FSTL1 is increased in patients with heart failure and acute coronary syndrome (98,99); therefore, it is a potential biomarker for cardiovascular diseases (98,100). FSTL1 administration has been shown to reduce myocardial infarct size in ischemia/reperfusion injury models through suppressing TGF-β family protein BMP4 proinflammatory signaling (101). In addition, FSTL1 overexpression specifically in mouse hearts leads to resistance to pressure overload–induced hypertrophy. Cardiomyocyte-specific loss of FSTL1 exacerbates cardiac hypertrophy and heart dysfunction while not altering the basal phenotype (122). In contrast to the beneficial role of FSTL1, FSTL3 binds activin A and antagonizes its cardiac protective function. As a result, cardiac-specific loss of FSTL3 attenuates ischemia/reperfusion injury and pathological hypertrophy (78,102).

FIBROBLAST GROWTH FACTOR-21. Several fibroblast growth factors (FGFs), along with their receptors, are detectable in multiple cardiac cell types, and they regulate cardiac development and function in an autocrine/paracrine manner in mice and humans (123). Among them, a high level of circulating FGF-21 has been observed in human heart diseases, including acute myocardial infarction, coronary heart disease, heart failure, and diabetic cardiomyopathy (124–130); thus, FGF-21 is a potential biomarker for cardiovascular diseases. FGF-21 also plays an important role in cardiac metabolism and function through autocrine and/or paracrine mechanisms. Whole-body loss of FGF-21 reduced cardiac fatty acid oxidation and resulted in exacerbated hypertrophy induced by isoproterenol that was reversed by FGF-21 administration, which indicated the cardioprotective effect of FGF-21 in pathological hypertrophy (99). Beyond the cardiovascular system, FGF-21 is a well-established regulator of metabolic signaling in other tissues, including brown fat and the brain (127–130), and is being evaluated in metabolic disorders, including obesity and diabetes. An analog of FGF-21, LY2405319, demonstrated improved in dyslipidemia and body weight in obese patients with type 2 diabetes (131).

INTERLEUKIN-33. Inflammatory response is one of the most notable processes occurring in many forms of heart disease and involves numerous inflammatory cytokines. Among them, cardiac interleukin-33 synthesis and secretion is induced mostly in cardiac fibroblasts by biomechanical stimuli, and it activates its receptor, suppression of tumorigenesis-2 (ST2), which is expressed on cardiomyocytes in a paracrine manner. Disruption of interleukin-33 signaling by deleting ST2 systemically or cardiac specifically exacerbates hypertrophic and fibrosis phenotypes induced by pressure overload injury (103,104). A soluble isoform of ST2 generated by alternative splicing was reported to be released into circulation and can function as a decoy receptor for interleukin-33 in the myocardium (103). The circulating soluble isoform of ST2 has emerged as a biomarker for multiple heart diseases, including acute myocardial infarction and heart failure (132–134), and the corresponding soluble isoform of ST2 immunoassay has been widely used clinically.

MicroRNA. Micro-RNAs (miRNAs) are noncoding RNAs of 18 to 25 nucleotides that are involved in posttranscriptional regulation by binding to the 3’ untranslated region of the target mRNA. miRNAs produced by cardiac cells can be encapsulated into exosomes or microvesicles and mediate cell–cell communication in hearts in an autocrine or paracrine fashion (135–138). Several cardiac-enriched miRNAs that exist predominantly in exosomes are highly elevated in the serum of patients with heart diseases. Circulating miRNA-1, miRNA-208a/b, miRNA-499, or miRNA-30a have been shown to be significantly increased in both mouse models and patients with acute myocardial infarction, thus emerging as potential biomarkers for cardiovascular diseases (107–111).

CARDIAC ENDOCRINOLOGY: KEY QUESTIONS AND FUTURE DIRECTIONS

Since the original discoveries of ANP/BNP, recent studies of GDF-15 and other possible heart-derived hormones have reinforced the importance of the endocrine function of the heart. Looking back, this probably should not be surprising. The heart is such a vital organ for the survival of an individual organism, that its health and functional status should be closely monitored and signaled to the rest of the body. Moreover, the heart occupies the best “real estate” in the whole circulatory system, and endocrine hormones are effective ways for the heart to communicate with other organs.

The striking similarity among various cardiac-derived endocrine hormones in terms of their biochemical modification, regulation, function, and clinical relevance illustrates the common features
of heart-derived hormones (Figure 1, Central Illustration). Among these features, the most important include: 1) their cardiac synthesis, maturation, secretion, and circulating levels are regulated in response to changing external cardiac demand or internal cardiac function (e.g., heart disease); and 2) their biological functions involve coordinating changes of cardiac function and demand—including vasodilation by ANP/BNP to reduce cardiac resistance and inhibition of body size by GDF-15 to mitigate cardiac burden, which are both used to cope with decreasing cardiac function due to disease and help prevent further deterioration of heart health (Central Illustration). Such coordination and homeostatic functions may well represent the fundamental biology of heart-derived hormones.

We believe that many additional heart-derived hormones remain to be discovered. The identification of new cardiac hormonal signals and further investigation of their regulation, signaling, function, and clinical significance will continue to provide novel biological insights into the many intricate communication mechanisms between the heart and other organs underlying their “symbiotic” relations. As demonstrated by GDF-15, myostatin, and ANP/BNP, these additional heart-derived hormones will also likely be of significant clinical importance as therapeutic targets or biomarkers of certain disease. We propose that the insights learned from GDF-15, myostatin, and ANP/BNP will guide the discovery and understanding of additional heart-derived hormones. An unbiased systemic screen can identify heart cell–secreted factors that match these common features (Central Illustration). Functional studies using approaches such as cardiac cell-specific transgenic/knock-out animal models and parabiosis can further demonstrate their biological significance and endocrine nature. Last, their clinical significance and therapeutic value can be explored based on their biological function and regulatory mechanisms.

Recent single-cell/nucleus transcriptomic analysis has revealed that only a portion of cardiomyocytes or other cardiac cell types synthesize cardiac hormones (27). This raises a few fundamental questions in cardiac endocrinology: are there specific populations of cardiac cells that tend to gain significant hormone synthesizing and secreting capabilities? If so, what are the internal genetic components and external signals that drive their endocrine-like functions? Just as our understanding of insulin is incomplete without studying pancreatic β cells, studies of potential cardiac endocrine cells will significantly enhance our understanding of heart-derived hormones and advance the field of cardiac endocrinology. We think that the fast-developing single-cell multiomics techniques (139-141) will be instrumental in moving the field forward. Single-cell transcriptome analysis will identify cells that show increased expression of hormones, processing enzymes (e.g., PCSK proteins), and even secretory machineries (endoplasmic reticulum, Golgi, and so on) following various stimuli; single-cell epigenome analysis will further discover the regulatory mechanisms and extracellular signals that promote the endocrine function of these cells.

CONCLUSIONS

In summary, historical and recent discoveries revealed the importance of the endocrine function of the heart. Studies of various heart-derived hormones highlighted their shared fundamental features and pointed to a unified endocrine mechanism that the heart uses to communicate with the rest of the body. The answers to many exciting basic and translational questions will further advance the field of cardiac endocrinology.

ACKNOWLEDGMENTS The authors thank Dan Kelly, Zolt Arany, Matt Weitzman, and Patrick Seale for their comments of this review.

ADDRESS FOR CORRESPONDENCE: Dr. Liming Pei, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, CTRB 6018, 3501 Civic Center Boulevard, Philadelphia, Pennsylvania 19104. E-mail: lpei@pennmedicine.upenn.edu.

REFERENCES

1. de Bold AJ, Borenstein HB, Veress AT, Sonnemberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
2. Soda T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
3. Okawa S, Imai M, Ueno A, et al. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature 1984;309:724-6.
4. Wang T, Liu J, McDonald C, et al. GDF15 is a heart-derived hormone that regulates body growth. EMBO Mol Med 2017;9:1150–64.
5. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
6. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;94:11514-9.
Cardiac Endocrinology: Heart-Derived Hormones

7. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997;1354:40-4.

8. Lawton LN, Bonaldo MF, Jelenc PC, et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 1997;203:17-26.

9. Paralkar VM, Vai AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998;273:13760-7.

10. Patel S, Alvarez-Guaita A, Melvin A, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab 2019;29:707-18.e8.

11. Nakamura T, Scialla A, Stephen C, et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissue. Br J Cancer 2003;88:1101-4.

12. Luan HJ, Wang A, Hillard BK, et al. GDF5 is an inflammation-induced central mediator of tissue tolerance. Cell 2019;178:1231-44 e11.

13. Eggers KM, Kempf T, Lagerqvist B, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010;3:88-96.

14. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and progression in the Valsartan Heart Failure Trial. Circulation 2010;122:138-95.

15. Wollert KC, Kempf T, Wallentin L. Growth-differentiation factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-60.

16. Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006;98:342-50.

17. Frikke-Schmidt H, Hultman K, Galaske JW, et al. Myostatin activation in patients with advanced heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007;53:284-91.

18. Couture F, Sabbagh R, Kwiatkowska A, et al. GDF15 and energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab 2018;28:353-68.

19. Tsai VW, Husaini Y, Sainsbury A, Brown DA, Brexit SN. The MIC-1/GDF5-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab 2018;28:353-68.

20. Tsai VW, Husaini Y, Manandhar R, et al. Anorexia/cachexia of chronic diseases: a role for the TGF-beta family cytokine MIC-1/GDF5. J Cell Physiol 2012;227:3-25.

21. Sharma M, Kambadur R, Matthews KG, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999;180:1-9.

22. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001;98:9306-11.

23. Wollman NM, McPherron AC, Pappano WN, et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A 2003;100:15842-6.

24. Anderson SB, Goldberg AL, Whitman M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 2008;283:7027-35.

25. Aylou T, Martinez-Hackert E. Transforming growth factor-beta family ligands can function as antagonists by competing for type II receptor binding. J Biol Chem 2016;291:10792-804.

26. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-8.

27. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-8.

28. Hill EW, McGivney BA, Gu J, Whitson R, Machugh DE. A genome-wide SNP-association study confirms a sequence variant (g. 66493737C>T) in the equine myostatin (MSTN) gene as the most powerful predictor of optimum racing distance for thoroughbred racehorses. BMC Genomics 2010;11:552.

29. Willems SM, Wright DJ, Day FR, et al. Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness. Nat Commun 2017;8:16015.

30. Heinrich J, Auger-Messier M, Xu J, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010;121:419-25.

31. Castillo E, Akashi H, Wang C, et al. Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle atrophy by atrophy. Biochim Biophys Acta 2015;1857:626-33.

32. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia beyond. Trends Endocrinol Metab 2018;29:560-70.
in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14:323–41.

54. Chen S, Cao P, Dong N, et al. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015;21:1048–53.

55. Wilcox JN, Augustine A, Goeddel DV, Lowe DG. Differential regional expression of three natriuretic peptide receptors genes within primate tissues. Mol Cell Biol. 1991;11:3454–62.

56. Lowe DG, Chang MS, Hellmiss R, et al. Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 1989;8:1377–84.

57. Nagase M, Katafuchi T, Hirose S, Fujita T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertension 1997; 15:1235–43.

58. Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 1989;341:68–72.

59. Chinkers M, Garbers DL, Chang MS, et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989;338: 78–83.

60. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endoclin Rev 2006;27:47–72.

61. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238:675–8.

62. Matsukawa N, Grzesik WJ, Takahashi N, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A 1999;96:7403–8.

63. Nussenzveig DR, Lewicki JA, Maack T. Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor. J Biol Chem 1999;265:20952–8.

64. Pankow K, Wang Y, Gembardt F, et al. Successive action of meprin A and npeprin catabolizes B-type natriuretic peptide. Circ Res 2007;101: 875–82.

65. Yandle TG, Brennan SO, Espiner EA, Nicholls MG, Richards AM. Endopeptidase-24.11 in human plasma degrades atrial natriuretic factor. Clin Chem 2009;55: 5734–45.

66. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996;31:7–18.

67. Ibebuogu UN, Gladysheva IP, Houng AK, et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989;338: 78–83.

68. Bayes-Genis A, Barallat J, Galan A, et al. Soluble npeprin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65: 657–65.

69. Owens AT, Brozena S, Jessup M. Npeprin inhibitors: emerging therapy for heart failure. Ann Rev Med 2017;68:41–9.

70. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci 2019;20:.

71. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-11-reprenren inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.

72. Holmgren CE, van Royo E, Johnson DB, et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 2012;149: 830–17.

73. House SL, Wang J, Castro AM, Weinheimer C, Kovacs A, Omitz DM. Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury. Physiol Rev 2015;3:611778.

74. Schnappauf D, Zile M, Zhou M, et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003;108:3140–8.

75. Wang ZG, Wang Y, Huang Y, et al. bFGF regulates autophagy and ubiquitinproteasome protein accumulation induced by myocardial ischemia/ reperfusion via the activation of the PI3K/Akt/mTOR pathway. Sci Rep 2015;5:9287.

76. Planavalia A, Redondo I, Toddare E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013;4: 2019.

77. Planavalia A, Redondo-Angulo I, Villarroya F, FGF21 and cardiac physiopathology. Front Endocrinol 2015;6:133.

78. Leithner-Nestler M, Grosse Siemer R, Fastab F, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transpl 2016;31:1088–99.

79. Richter M, Lautze HJ, Walther T, Braun T, Kostin S, Kubin T. The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J Heart Lung Transpl 2017;36: 1217–24.

80. Widera C, Giannitsis E, Kempf T, et al. Cardiac-specific overexpression of fibroblast growth factor 21 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation 2011;123:504–14.

81. Matsumoto E, Sasaki K, Kinosita H, et al. Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16. Genes Cells 2013;18:544–53.

82. Kalra PR, Clague JR, Bolger AP, et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003;107: 571–3.

83. Wang Y, de Waard MC, Sterner-Kock A, et al. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 2009;11:548–57.

84. Seo K, Kishimoto I, Okumura H, et al. C-type natriuretic peptide, a novel antiinflammatory and anti hypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005;45:608–16.

85. Moyes AJ, Chu SM, Aubdoo AA, et al. C-type natriuretic peptide co-ordinates cardiac structure and function. Eur Heart J 2020;41:1006–20.

86. Lumsden NG, Kambata RS, Hobbs AJ. C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr Pharmaceut Design 2010;16:4080–8.

87. Zhao A, Zhao X, Li T, et al. CTRPP knockout exaggerates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy through inhibiting the LHBD/AMPK pathway. J Cell Mol Med 2020;24:2635–47.

88. Appani M, Breitbart A, Brandes F, et al. Clq-TNF-related protein-9 promotes cardiac hypertrophy and failure. Circ Res 2017;120:66–77.

89. Zhao XS, Fan W, Bekerjian R, Sholet RV. Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 2006;114: 830–7.

90. House SL, Botle C, Zhou M, et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 2003;108:3140–8.

91. Pankow K, Wang Y, Gembardt F, et al. Successive action of meprin A and npeprin catabolizes B-type natriuretic peptide. Circ Res 2007;101: 875–82.

92. Yandle TG, Brennan SO, Espiner EA, Nicholls MG, Richards AM. Endopeptidase-24.11 in human plasma degrades atrial natriuretic factor (ANF) to ANF(99-105)/106-126). Peptides 1989; 10:891–4.

93. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996;31:7–18.

94. Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail 2011;4:114–20.

95. Bayes-Genis A, Barallat J, Galan A, et al. Soluble npeprin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65: 657–65.
as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin Chem 2012;58:1233–41.

101. Ogura Y, Ouchi N, Ohashi K, et al. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 2012;126:1728–38.

102. Shimano M, Ouchi N, Nakamura K, et al. Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy. J Biol Chem 2011;286:9840–8.

103. Sanada S, Halko D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538–49.

104. Chen WY, Hong J, Gannon J, Kakkar R, Lee RT. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc Natl Acad Sci U S A 2015;112:7249–54.

105. Tadimalla A, Belmont PJ, Thuerauf DJ, et al. Mesencephalic astrocyte-derived neurotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart. Circ Res 2008;103:1249–58.

106. Glembotski CC. Functions for the cardiomyocyte, MANF, in cardioprotection, hypertrophy and heart failure. J Mol Cell Cardiol 2011;51:512–7.

107. Cheng M, Yang J, Zhao X, et al. Circulating myocardial microRNAs to diagnose acute myocardial infarction. Circ Res 2010;107:2765–73.

108. Wang Gk, Zhu JQ, Zhang JT, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010;31:659–66.

109. Devaux Y, Vassort M, Geretti E, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chim 2012;58:559–67.

110. Yang Y, Li Y, Chen X, Cheng X, Liao Y, Yu X. Exosomal transfer of mir-30a between cardiomyocytes regulates autophagy after hypoxia. J Mol Med 2016;94:711–24.

111. Frost RJ, Engelhardt S. A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation 2007;116:1768–75.

112. Mastri M, Shah Z, Hsieh K, et al. Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention. Am J Physiol Cell Physiol 2014;306:C531–9.

113. Martin S, Lin H, Ejimadu C, Lee T. Tissuespecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts. Am J Physiol Cell Physiol 2015;309:C139–47.

114. 114. Askevold ET, Aukrust P, Nyno SH, et al. The cardioline secreted Frizzled-related protein 3, a modulator of Wnt signaling, in clinical and experimental heart failure. J Intern Med 2014;275:321–30.

115. Ueland T, Cardahl K, Askevold ET, Karlsson T, Hartford M, Aukrust P. Secreted Frizzled-related protein 3 (sFRP3) in acute coronary syndromes. Int J Cardiol 2015;190:217–9.

116. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863–70.

117. Sugah S, Nakao K, Itoh H, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of “vascular natriuretic peptide system”. J Clin Invest 1992;90:1145–9.

118. Del Ry S, Cabrini M, Lioniatti V, Emdin M, Recchia FA, Giannesi D. Expression of C-type natriuretic peptide and its receptor NPR-B in normal and failing heart. Peptides 2008;29:2208–15.

119. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: possible existence of “vascular natriuretic peptide system”. J Am Coll Cardiol 2008;51:1227–33.

120. Aimo A, Januzzi JL Jr., Bayes-Genis A, et al. Clinical and prognostic significance of sST2 in heart failure. JACC review topic of the week. J Am Coll Cardiol 2019;74:2193–203.

121. Bang C, Batkal S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014;124:2136–46.

122. Wang X, Huang W, Liu G, et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol 2014;74:139–50.

123. Garcia NA, Moncayo-Arlandi J, Sepulveda P, Diez-Juan A. Cardiomyocyte exosomes regulate glycolytic flux in endothelium by direct transfer of GLUT transporters and glycolytic enzymes. Cardiovasc Res 2016;109:397–408.

124. Yang J, Yu X, Xue F, Li Y, Liu W, Zhang S. Exosomes derived from cardiomyocytes promote cardiac fibrosis via myocyte-fibroblast cross-talk. Am J Transl Res 2018;10:4350–66.

125. Cao J, Cusanovich DA, Ramani V, et al. Joint profiling of chromatin accessibility and gene expression in thousands of single cells. Science 2018;361:1380–5.

126. Granja AM, Klemm S, McGinnis LM, et al. Single-cell multimodal analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nat Biotechnol 2019;37:1458–65.

127. Chen S, Lake BB, Zhang K. High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell. Nat Biotechnol 2019;37:1452–7.

**KEY WORDS** cardiac endocrinology, GDF15, heart, heart-derived hormones